

# Domenica Taruscio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/192725/publications.pdf>

Version: 2024-02-01

150  
papers

4,452  
citations

101384

36  
h-index

143772

57  
g-index

155  
all docs

155  
docs citations

155  
times ranked

6878  
citing authors

#	ARTICLE	IF	CITATIONS
1	Technologies to Support Frailty, Disability, and Rare Diseases: Towards a Monitoring Experience during the COVID-19 Pandemic Emergency. <i>Healthcare (Switzerland)</i> , 2022, 10, 235.	1.0	1
2	COVID-19 and the rare disease organization response during pandemic: the "Italian model"™. <i>Future Rare Diseases</i> , 2022, 2, .	0.1	0
3	Expanded newborn bloodspot screening: developed country examples and what can be done in Turkey. <i>Intractable and Rare Diseases Research</i> , 2022, 11, 63-69.	0.3	5
4	Multifactorial Rare Diseases: Can Uncertainty Analysis Bring Added Value to the Search for Risk Factors and Etiopathogenesis?. <i>Medicina (Lithuania)</i> , 2021, 57, 119.	0.8	2
5	Reflections on the Importance of Cost of Illness Analysis in Rare Diseases: A Proposal. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1101.	1.2	8
6	CPMS"improving patient care in Europe via virtual case discussions. <i>Endocrine</i> , 2021, 71, 549-554.	1.1	13
7	Shaping national plans and strategies for rare diseases in Europe: past, present, and future. <i>Journal of Community Genetics</i> , 2021, 12, 207-216.	0.5	9
8	Progress, challenges and global approaches to rare diseases. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2021, 110, 2711-2716.	0.7	37
9	Congenital anomalies: Can One Health reduce the community burden?. <i>Reproductive Toxicology</i> , 2021, 104, 166-167.	1.3	1
10	The Quality Evaluation of Rare Disease Registries"An Assessment of the Essential Features of a Disease Registry. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11968.	1.2	11
11	A call for global action for rare diseases in Africa. <i>Nature Genetics</i> , 2020, 52, 21-26.	9.4	31
12	The case for open science: rare diseases. <i>JAMIA Open</i> , 2020, 3, 472-486.	1.0	33
13	Shaping the Future of Rare Diseases after a Global Health Emergency: Organisational Points to Consider. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8694.	1.2	9
14	The EuRECa Project as a Model for Data Access and Governance Policies for Rare Disease Registries That Collect Clinical Outcomes. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8743.	1.2	13
15	Social Economic Costs, Health-Related Quality of Life and Disability in Patients with Cri Du Chat Syndrome. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5951.	1.2	6
16	Improving diagnosis for rare diseases: the experience of the Italian undiagnosed Rare diseases network. <i>Italian Journal of Pediatrics</i> , 2020, 46, 130.	1.0	14
17	Primary Sclerosing Cholangitis: Burden of Disease and Mortality Using Data from the National Rare Diseases Registry in Italy. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3095.	1.2	17
18	The Italian External Quality Assessment Program for Cystic Fibrosis Sweat Chloride Test: Does Active Participation Improve the Quality?. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3196.	1.2	2

#	ARTICLE	IF	CITATIONS
19	The Italian National Rare Diseases Registry: a model of comparison and integration with Hospital Discharge Data. <i>Journal of Public Health</i> , 2019, 41, 46-54.	1.0	8
20	Primary prevention as an essential factor ensuring sustainability of health systems: the example of congenital anomalies. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2019, 55, 258-264.	0.2	5
21	The RD-Connect Registry & Biobank Finder: a tool for sharing aggregated data and metadata among rare disease researchers. <i>European Journal of Human Genetics</i> , 2018, 26, 631-643.	1.4	33
22	Future of Rare Diseases Research 2017â€“2027: An IRDiRC Perspective. <i>Clinical and Translational Science</i> , 2018, 11, 21-27.	1.5	154
23	Meeting Patientsâ€™ Right to the Correct Diagnosis: Ongoing International Initiatives on Undiagnosed Rare Diseases and Ethical and Social Issues. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 2072.	1.2	40
24	The Occurrence of 275 Rare Diseases and 47 Rare Disease Groups in Italy. Results from the National Registry of Rare Diseases. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1470.	1.2	15
25	The Genomic Medicine Alliance: A Global Effort to Facilitate the Introduction of Genomics into Healthcare in Developing Nations. , 2018, , 173-188.		1
26	Recommendations for Improving the Quality of Rare Disease Registries. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1644.	1.2	116
27	International Cooperation to Enable the Diagnosis of All Rare Genetic Diseases. <i>American Journal of Human Genetics</i> , 2017, 100, 695-705.	2.6	305
28	Data Quality in Rare Diseases Registries. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1031, 149-164.	0.8	56
29	Improved Diagnosis and Care for Rare Diseases through Implementation of Precision Public Health Framework. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1031, 55-94.	0.8	20
30	Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements. <i>Public Health Genomics</i> , 2017, 20, 1-8.	0.6	15
31	The Role of Solidarity(-ies) in Rare Diseases Research. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1031, 589-604.	0.8	9
32	Primary Prevention of Congenital Anomalies: Special Focus on Environmental Chemicals and other Toxicants, Maternal Health and Health Services and Infectious Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1031, 301-322.	0.8	10
33	Health Systems Sustainability and Rare Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1031, 629-640.	0.8	2
34	Undiagnosed Diseases: Italy-US Collaboration and International Efforts to Tackle Rare and Common Diseases Lacking a Diagnosis. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1031, 25-38.	0.8	17
35	Linked Registries: Connecting Rare Diseases Patient Registries through a Semantic Web Layer. <i>BioMed Research International</i> , 2017, 2017, 1-13.	0.9	28
36	Initiating an undiagnosed diseases program in the Western Australian public health system. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 83.	1.2	24

#	ARTICLE	IF	CITATIONS
37	Sustainable public health systems for rare diseases. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2017, 53, 170-175.	0.2	2
38	Patient-physician alliance: from Hippocrates to Post-Genomic Era. Commentary. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2017, 53, 93-95.	0.2	0
39	The risk of re-identification versus the need to identify individuals in rare disease research. <i>European Journal of Human Genetics</i> , 2016, 24, 1553-1558.	1.4	46
40	Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy. <i>Public Health Genomics</i> , 2016, 19, 352-363.	0.6	37
41	Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 31-42.	1.4	50
42	Social/economic costs and health-related quality of life in patients with scleroderma in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 109-117.	1.4	28
43	Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 19-29.	1.4	59
44	The Quality of Rare Disease Registries: Evaluation and Characterization. <i>Public Health Genomics</i> , 2016, 19, 108-115.	0.6	16
45	Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 99-108.	1.4	31
46	Social/economic costs and quality of life in patients with haemophilia in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 53-65.	1.4	53
47	Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 7-18.	1.4	38
48	Social/economic costs and health-related quality of life in patients with histiocytosis in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 67-78.	1.4	16
49	Expanded Newborn Screening: A Chess Board Motif in Public Health. <i>Journal of Pediatric Biochemistry</i> , 2016, 06, 066-070.	0.2	1
50	Overview of existing initiatives to develop and improve access and data sharing in rare disease registries and biobanks worldwide. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 729-739.	0.5	6
51	Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 43-52.	1.4	35
52	Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 89-98.	1.4	41
53	The Italian pilot external quality assessment program for cystic fibrosis sweat test. <i>Clinical Biochemistry</i> , 2016, 49, 601-605.	0.8	8
54	Improving the informed consent process in international collaborative rare disease research: effective consent for effective research. <i>European Journal of Human Genetics</i> , 2016, 24, 1248-1254.	1.4	47

#	ARTICLE	IF	CITATIONS
55	Policies on Conflicts of Interest in Health Care Guideline Development: A Cross-Sectional Analysis. PLoS ONE, 2016, 11, e0166485.	1.1	28
56	Parent training education program: a pilot study, involving families of children with Prader-Willi syndrome. Annali Dell'Istituto Superiore Di Sanita, 2016, 52, 428-433.	0.2	2
57	National Registries of Rare Diseases in Europe: An Overview of the Current Situation and Experiences. Public Health Genomics, 2015, 18, 20-25.	0.6	30
58	Undiagnosed Diseases Network International (UDNI): White paper for global actions to meet patient needs. Molecular Genetics and Metabolism, 2015, 116, 223-225.	0.5	69
59	European Reference Networks and Guideline Development and Use: Challenges and Opportunities. Public Health Genomics, 2015, 18, 318-320.	0.6	4
60	Recruitment procedures for descriptive socio-economic studies in rare diseases. The BURQOL-RD project. Expert Opinion on Orphan Drugs, 2015, 3, 759-765.	0.5	8
61	Rare Disease Registries Classification and Characterization: A Data Mining Approach. Public Health Genomics, 2015, 18, 113-122.	0.6	21
62	Primary Prevention of Congenital Anomalies: Recommendable, Feasible and Achievable. Public Health Genomics, 2015, 18, 184-191.	0.6	23
63	National Plans on Rare Diseases. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 1-22.	0.6	1
64	Rare Diseases Research and Practice. Endocrine Development, 2014, 27, 234-256.	1.3	12
65	A framework to start the debate on neonatal screening policies in the EU: an Expert Opinion Document. European Journal of Human Genetics, 2014, 22, 12-17.	1.4	49
66	Characterization and classification of Rare Disease Registries by using exploratory data analyses. Orphanet Journal of Rare Diseases, 2014, 9, P4.	1.2	1
67	The EPIRARE proposal of a set of indicators and common data elements for the European platform for rare disease registration. Archives of Public Health, 2014, 72, 35.	1.0	41
68	European Recommendations for Primary Prevention of Congenital Anomalies: A Joined Effort of EUROCAT and EUROPLAN Projects to Facilitate Inclusion of This Topic in the National Rare Disease Plans. Public Health Genomics, 2014, 17, 115-123.	0.6	39
69	RD-Connect: An Integrated Platform Connecting Databases, Registries, Biobanks and Clinical Bioinformatics for Rare Disease Research. Journal of General Internal Medicine, 2014, 29, 780-787.	1.3	159
70	Centres of Expertise and European Reference Networks: key issues in the field of rare diseases. The EUCERD Recommendations. Blood Transfusion, 2014, 12 Suppl 3, s621-5.	0.3	14
71	The social burden and quality of life of patients with haemophilia in Italy. Blood Transfusion, 2014, 12 Suppl 3, s567-75.	0.3	22
72	The Italian National Rare Diseases Registry. Blood Transfusion, 2014, 12 Suppl 3, s606-13.	0.3	18

#	ARTICLE	IF	CITATIONS
73	Haemophilia Centre Certification Systems: optional or optimal choice for healthcare systems?. Blood Transfusion, 2014, 12 Suppl 3, s492-4.	0.3	0
74	The Italian National Centre for Rare Diseases: where research and public health translate into action. Blood Transfusion, 2014, 12 Suppl 3, s591-605.	0.3	4
75	The Current Situation and Needs of Rare Disease Registries in Europe. Public Health Genomics, 2013, 16, 288-298.	0.6	33
76	The Italian National External Quality Assessment Program in Molecular Genetic Testing: Results of the VII Round (2010-2011). BioMed Research International, 2013, 2013, 1-8.	0.9	4
77	A Model for the European Platform for Rare Disease Registries. Public Health Genomics, 2013, 16, 299-304.	0.6	16
78	EUROPLAN: A Project to Support the Development of National Plans on Rare Diseases in Europe. Public Health Genomics, 2013, 16, 278-287.	0.6	15
79	Editorial. Public Health Genomics, 2013, 16, 257-258.	0.6	1
80	The TREAT-NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia. Human Mutation, 2013, 34, 1449-1457.	1.1	94
81	Modeling delay in diagnosis of NF: under reporting, incidence and prevalence estimates. Journal of Applied Statistics, 2012, 39, 711-721.	0.6	1
82	Predictive medicine and biomarkers: the case of rare diseases. Personalized Medicine, 2012, 9, 143-146.	0.8	3
83	Classification and codification of rare diseases. Journal of Clinical Epidemiology, 2012, 65, 1026-1027.	2.4	8
84	Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study. Health Policy, 2012, 108, 19-26.	1.4	38
85	Modeling delay to diagnosis for Amyotrophic lateral sclerosis: under reporting and incidence estimates. BMC Neurology, 2012, 12, 160.	0.8	12
86	Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2 "From screening laboratory results to treatment, follow-up and quality assurance. Journal of Inherited Metabolic Disease, 2012, 35, 613-625.	1.7	88
87	The need for worldwide policy and action plans for rare diseases. Acta Paediatrica, International Journal of Paediatrics, 2012, 101, 805-807.	0.7	69
88	Europe and the century of biomedical discovery and implementation. Lancet, The, 2011, 377, 719-720.	6.3	3
89	Streptococcus Suis: A Potential Risk Factor for Salivary Gland Tumors?. International Journal of Biological Markers, 2011, 26, 278-280.	0.7	1
90	Three cases of rare salivary gland tumours: a molecular study of TP53, CDKN2A/ARF, RAS, BRAF, PTEN, MAPK2 and EGFR genes. Oncology Reports, 2011, 26, 3-11.	1.2	42

#	ARTICLE	IF	CITATIONS
91	Oxidative stress activation of miR-125b is part of the molecular switch for Hailey-Hailey disease manifestation. <i>Experimental Dermatology</i> , 2011, 20, 932-937.	1.4	57
92	Folic acid and primary prevention of birth defects. <i>BioFactors</i> , 2011, 37, 280-284.	2.6	27
93	Mortality associated with neurofibromatosis type 1: A study based on Italian death certificates (1995-2006). <i>Orphanet Journal of Rare Diseases</i> , 2011, 6, 11.	1.2	44
94	The Role of microRNAs in the Biology of Rare Diseases. <i>International Journal of Molecular Sciences</i> , 2011, 12, 6733-6742.	1.8	13
95	Rare diseases and orphan drugs. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2011, 47, 83-93.	0.2	25
96	Quality of Life Assessment in Prader-Willi Syndrome. , 2011, , 3153-3162.		0
97	In utero exposure to di-(2-ethylhexyl) phthalate affects liver morphology and metabolism in post-natal CD-1 mice. <i>Reproductive Toxicology</i> , 2010, 29, 427-432.	1.3	49
98	Complex multipathways alterations and oxidative stress are associated with Hailey-Hailey disease. <i>British Journal of Dermatology</i> , 2010, 162, 518-526.	1.4	35
99	MicroRNA profiling of multiple osteochondromas: identification of disease-specific and normal cartilage signatures. <i>Clinical Genetics</i> , 2010, 78, 507-516.	1.0	35
100	National Plans and Strategies on Rare Diseases in Europe. <i>Advances in Experimental Medicine and Biology</i> , 2010, 686, 475-491.	0.8	28
101	The Italian External Quality Control Program for Familial Adenomatous Polyposis of the Colon: Five Years of Experience. <i>Genetic Testing and Molecular Biomarkers</i> , 2010, 14, 175-181.	0.3	2
102	Identification of Key Regions and Genes Important in the Pathogenesis of Sjögren Syndrome by Combining Genomic and Expression Microarrays. <i>Cancer Research</i> , 2009, 69, 8438-8446.	0.4	68
103	Health-Related Quality of Life in Patients with Neurofibromatosis Type 1. <i>Dermatology</i> , 2009, 218, 215-220.	0.9	73
104	Availability of medicines for rare diseases in EU Countries. <i>Pharmaceuticals Policy and Law</i> , 2009, 11, 101-109.	0.1	7
105	The Task-force in Europe for Drug Development for the Young (TEDDY) Network of Excellence. <i>Paediatric Drugs</i> , 2009, 11, 18-21.	1.3	15
106	The Italian Scheme of External Quality Assessment for $\beta$ -Thalassemia: Genotyping and Reporting Results and Testing Strategies in a 5-Year Survey. <i>Genetic Testing and Molecular Biomarkers</i> , 2009, 13, 31-36.	0.3	6
107	Altered microRNA Expression Patterns in Hepatoblastoma Patients. <i>Translational Oncology</i> , 2009, 2, 157-163.	1.7	68
108	Maternal diet and the risk of hypospadias and cryptorchidism in the offspring. <i>Paediatric and Perinatal Epidemiology</i> , 2008, 22, 249-260.	0.8	45

#	ARTICLE	IF	CITATIONS
109	The Italian External Quality Assessment Scheme in Classical Cytogenetics: Four Years of Activity. <i>Public Health Genomics</i> , 2008, 11, 295-303.	1.0	5
110	The Italian External Quality Assessment Scheme for Fragile X Syndrome: The Results of a 5-Year Survey. <i>Genetic Testing and Molecular Biomarkers</i> , 2008, 12, 279-288.	1.7	7
111	Molecular link(s) between hepatoblastoma pathogenesis and exposure to di-(2-ethylhexyl)phthalate: a hypothesis. <i>Folia Medica</i> , 2008, 50, 17-23.	0.2	3
112	The Italian External Quality Control Programme for cystic fibrosis molecular diagnosis: 4 years of activity. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 254-60.	1.4	7
113	Report of an International Survey of Molecular Genetic Testing Laboratories. <i>Public Health Genomics</i> , 2007, 10, 123-131.	0.6	20
114	A case report of a patient with microcephaly, facial dysmorphism, chromosomal radiosensitivity and telomere length alterations closely resembling "Nijmegen breakage syndrome" phenotype. <i>European Journal of Medical Genetics</i> , 2007, 50, 176-187.	0.7	13
115	EQUAL-qual: A European Program for External Quality Assessment of Genomic DNA Extraction and PCR Amplification. <i>Clinical Chemistry</i> , 2007, 53, 1349-1357.	1.5	27
116	Quality of life assessment in a sample of patients affected by Prader-Willi syndrome. <i>Journal of Paediatrics and Child Health</i> , 2007, 43, 826-830.	0.4	29
117	The possible role of endocrine disrupting chemicals in the aetiology of cryptorchidism and hypospadias: a population-based case-control study in rural Sicily. <i>Journal of Developmental and Physical Disabilities</i> , 2007, 30, 3-13.	3.6	82
118	Tackling rare diseases at European level: why do we need a harmonized framework?. <i>Folia Medica</i> , 2007, 49, 59-67.	0.2	10
119	Cryptorchidism and hypospadias in the Sicilian district of Ragusa and the use of pesticides. <i>Reproductive Toxicology</i> , 2006, 22, 8-12.	1.3	70
120	Chromosomal alterations detected by comparative genomic hybridization in nonfunctioning endocrine pancreatic tumors. <i>Cancer Genetics and Cytogenetics</i> , 2005, 156, 23-30.	1.0	28
121	Quality assessment in cytogenetic and molecular genetic testing: the experience of the Italian Project on Standardisation and Quality Assurance. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 915-21.	1.4	23
122	Factors regulating endogenous retroviral sequences in human and mouse. <i>Cytogenetic and Genome Research</i> , 2004, 105, 351-362.	0.6	38
123	Tackling the Problem of Rare Diseases in Public Health: The Italian Approach. <i>Public Health Genomics</i> , 2003, 6, 123-124.	0.6	8
124	A new polymorphism in the flanking region of human VAMP2 and hPer1 genes. <i>Molecular and Cellular Probes</i> , 2002, 16, 391-392.	0.9	6
125	Organization and integration sites in the human genome of endogenous retroviral sequences belonging to HERV-E family. <i>Mammalian Genome</i> , 2002, 13, 216-222.	1.0	18
126	A Population-Based Study on the Frequency of Additional Congenital Malformations in Infants with Congenital Hypothyroidism: Data from the Italian Registry for Congenital Hypothyroidism (1991-1998). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 557-562.	1.8	128



#	ARTICLE	IF	CITATIONS
127	Alteration of chromosome arm 6p is characteristic of primary mediastinal B-cell lymphoma, as identified by genome-wide allelotyping. <i>Genes Chromosomes and Cancer</i> , 2001, 31, 191-195.	1.5	26
128	Increased <i>c-met</i> Expression During Ductal $\beta^2$ Cell Neogenesis in Experimental Autoimmune Diabetes. <i>Growth Factors</i> , 2001, 19, 259-267.	0.5	6
129	Allelotype of pancreatic acinar cell carcinoma. <i>International Journal of Cancer</i> , 2000, 88, 772-777.	2.3	57
130	Pancreatic acinar carcinoma shows a distinct pattern of chromosomal imbalances by comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 2000, 28, 294-299.	1.5	27
131	The human <i>Per1</i> gene: genomic organization and promoter analysis of the first human orthologue of the <i>Drosophila</i> period gene. <i>Gene</i> , 2000, 253, 161-170.	1.0	23
132	Nonrandom chromosomal imbalances in primary mediastinal b-cell lymphoma detected by arbitrarily primed PCR fingerprinting. , 1999, 26, 203-209.		32
133	Human endogenous retroviruses and environmental endocrine disrupters: A connection worth exploring?. , 1998, 58, 27-28.		4
134	Human Endogenous Retroviral Sequences: Possible Roles in Reproductive Physiopathology1. <i>Biology of Reproduction</i> , 1998, 59, 713-724.	1.2	27
135	<i>Pst</i> I RFLP in the GABA $\beta_1$ receptor gene on human chromosome 6q. <i>Molecular and Cellular Probes</i> , 1997, 11, 309-310.	0.9	0
136	Nonrandom gain of chromosome 7 in central neurocytoma: A chromosomal analysis and fluorescence in situ hybridization study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1997, 430, 47-51.	1.4	36
137	Eleven chromosomal integration sites of a human endogenous retrovirus (HERV 4-1) map close to known loci of thirteen hereditary malformation syndromes. <i>Teratology</i> , 1996, 54, 108-110.	1.8	9
138	Numerical chromosomal aberrations in thyroid tumors detected by double fluorescence in situ hybridization. <i>Genes Chromosomes and Cancer</i> , 1994, 9, 180-185.	1.5	26
139	Cell Cycle-Dependent Distribution of Telomeres, Centromeres, and Chromosome-Specific Subsatellite Domains in the Interphase Nucleus of Mouse Lymphocytes. <i>Experimental Cell Research</i> , 1993, 205, 142-151.	1.2	159
140	Detection of Trisomy 12 on Ovarian Sex Cord Stromal Tumors by Fluorescence In Situ Hybridization. <i>Diagnostic Molecular Pathology</i> , 1993, 2, 94-98.	2.1	34
141	Genetic and physical map of the interferon region on chromosome 9p. <i>Genomics</i> , 1992, 14, 105-112.	1.3	52
142	Generation and characterization of a human chromosome 9 cosmid library. <i>Somatic Cell and Molecular Genetics</i> , 1992, 18, 269-284.	0.7	6
143	Human dopamine D5 receptor pseudogenes. <i>Gene</i> , 1991, 109, 211-218.	1.0	53
144	Evaluation of an experimental periodontal ligament for dental implants. <i>Biomaterials</i> , 1991, 12, 474-478.	5.7	7

#	ARTICLE	IF	CITATIONS
145	Increased reactivity of laminin in the basement membranes of capillary walls in AIDS brain cortex. Acta Neuropathologica, 1991, 81, 552-556.	3.9	9
146	Integration site preferences of endogenous retroviruses. Chromosoma, 1991, 101, 141-156.	1.0	76
147	Ultrastructure of the absorptive cell glycocalyx in hyperplastic colonic polyps after staining with Alcian Blue and high iron diamine. The Histochemical Journal, 1989, 21, 285-288.	0.6	0
148	Malignant histiocytosis (true histiocytic lymphoma) clinicopathological study of 25 cases. Histopathology, 1985, 9, 905-920.	1.6	46
149	Neoplastic and reactive follicles within B-cell malignant lymphomas. A morphological and immunological study of 30 cases. Hematological Oncology, 1985, 3, 243-260.	0.8	25
150	Current trends in biobanking for rare diseases: a review. Journal of Biorepository Science for Applied Medicine, 0, , 49.	0.2	16